Abstract
The biotech firm PharmEnable, which uses artificial intelligence in drug discovery, has raised $7.5 million in a preseries A funding round. The University of Cambridge spin-off is developing small molecules for diseases that are currently undruggable. PharmEnable’s platform is built on the concepts of chemical diversity and unexplored chemical space that two of the cofounders worked on in the lab of chemist David R. Spring. The firm will use the cash to expand in-house projects and partnerships focusing on cancer and neurology.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
